Who
Kevin Bitterman
Director
Company insider
Files Form 4 as: Director, Disc Medicine; Director, Akero Therapeutics; Director and 10% owner, Editas Medicine; Director, Genocea Biosciences.
In numbers
- Trades disclosed
- 174
- Buys
- 3
- Sells
- 44
- Bought
- $15.1M
- Sold
- $103.4M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 10 Feb 2014
- Last trade
- 21 Oct 2026
- Last filed
- 21 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Oct 2026filed 21 Oct 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $1.1M13,783 at $80.23 | filing |
| 21 Oct 2026filed 21 Oct 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $920K11,470 at $80.23 | filing |
| 21 Oct 2026filed 21 Oct 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $21K266 at $80.23 | filing |
| 20 Oct 2026filed 21 Oct 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $229K2,869 at $79.95 | filing |
| 20 Oct 2026filed 21 Oct 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $191K2,388 at $79.95 | filing |
| 20 Oct 2026filed 21 Oct 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $4,39755 at $79.95 | filing |
| 19 Oct 2026filed 21 Oct 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $475K5,937 at $79.97 | filing |
| 19 Oct 2026filed 21 Oct 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $395K4,942 at $79.97 | filing |
| 19 Oct 2026filed 21 Oct 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $9,197115 at $79.97 | filing |
| 11 Sep 2026filed 15 Sep 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Code M | $326K7,136 at $45.69 | filing |
| 11 Sep 2026filed 15 Sep 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Code M | $389K10,000 at $38.85 | filing |
| 11 Sep 2026filed 15 Sep 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Code M | $509K10,000 at $50.86 | filing |
| 11 Sep 2026filed 15 Sep 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,136 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Sold | $1.9M27,136 at $70.11 | filing |
| 11 Sep 2026filed 15 Sep 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,136 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | IRON Disc MedicineBiotechnology | SEC FORM 4 Code M | $326K7,136 at $45.69 | filing |
News
Disc Medicine (NASDAQ:IRON) Director Kevin Bitterman Sells 27,136 Sharesthemarketsdaily.com · 16 Sep 2026Disc Medicine (NASDAQ:IRON) Director Sells 10,994 Shares of StockIRON · themarketsdaily.com · 21 Oct 2026Disc Medicine Prices $450 Mln Offering Of Shares At $75/shr To Fund Pipeline DevelopmentIRON · finanzen.ch · 21 Oct 2026Disc Medicine Launches $350M Stock Offering Following Positive Phase 3 ResultsIRON · rttnews.com · 20 Oct 2026
1 headline in the last 90 days name Kevin Bitterman; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.